Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed non-muscle invasive bladder cancer \[Ta, T1 or Tis (CIS)\] that has been removed by transurethral resection~* Either: (i) high-risk disease, defined as T1 and/or high-grade and/or CIS or (ii) intermediate-risk disease, defined as Ta low-grade with at least 3 of the following 4 risk factors: multiple tumors, tumor size \> 3cm, early recurrence (\<1 year from previous staging procedure), or recurrence with a frequency of more than once in any 12 month period~* Not have received bacillus Calmette-Guérin (BCG) or have completed previous BCG treatment \> 12 months prior to the baseline staging procedure.~* Phase 2 Arms 1-3: Suitable to receive a 6-week course of BCG in the adjuvant setting within 6 weeks following TURBT. Phase 2 Arm 4: Suitable for monotherapy vaccine administration post-TURBT. For Phase 1 only: Has previously received 3-6 weekly doses of BCG.~* Adequate laboratory parameters~Exclusion Criteria:~* Human immunodeficiency virus (HIV) infection or immunodeficiency disorders, either primary or acquired~* Infections or intercurrent illness requiring active therapy~* Any condition requiring active steroid or other immunosuppressive therapy~* Active malignancies within the past 12 months except negligible risk of metastasis or death treated with expected curative outcome.~* Prostate pelvic radiation within the past 12 months~* Significant cardiac impairment~* Current alcohol or chemical abuse, or mental or psychiatric condition precluding protocol compliance~* Pregnant or nursing~* Allergy to soy, egg, or peanut products~* Receiving another investigational agent (30 day wash-out required prior to first dose)~* Neo-adjuvant therapy prior to baseline staging procedures for the current occurrence of non-muscle invasive bladder cancer~* Prior treatment with a cancer vaccine for this indication~* Prior vaccination with BCG for tuberculosis disease~* Prior splenectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I: HS-410 Low Dose (Type: EXPERIMENTAL): In the open label Phase 1 portion, HS-410 is given as 1\*10\^6 cells per dose for 12 weekly injections followed by 3 monthly injections.
- Phase II: HS-410 Low-Dose Plus BCG (Type: EXPERIMENTAL): In the Phase 2 portion, HS-410 is given as 1\*10\^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
- Phase II: High-Dose HS-410 Plus BCG (Type: EXPERIMENTAL): In the Phase 2 portion, HS-410 is given as 1\*10\^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
- Phase II: Placebo Plus BCG (Type: PLACEBO_COMPARATOR): In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.
- Phase II: High-Dose HS-410 (Type: EXPERIMENTAL): In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1\*10\^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues